

# Stefano Barlati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3249830/publications.pdf>

Version: 2024-02-01

69  
papers

3,425  
citations

218381

26  
h-index

155451

55  
g-index

73  
all docs

73  
docs citations

73  
times ranked

4178  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. <i>Psychological Medicine</i> , 2023, 53, 3661-3671.	2.7	23
2	Internalized stigma among people with schizophrenia: Relationship with socio-demographic, clinical and medication-related features. <i>Schizophrenia Research</i> , 2022, 243, 364-371.	1.1	34
3	The impact of the Covid-19 pandemic on patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2022, 54, 62-64.	0.3	8
4	Autistic Symptoms in Schizophrenia: Impact on Internalized Stigma, Well-Being, Clinical and Functional Characteristics. <i>Frontiers in Psychiatry</i> , 2022, 13, 801651.	1.3	5
5	The Elephant in the Room: A Cross-Sectional Study on the Stressful Psychological Effects of the COVID-19 Pandemic in Mental Healthcare Workers. <i>Brain Sciences</i> , 2022, 12, 408.	1.1	23
6	Patterns of Care for Adolescent With Schizophrenia: A Delphi-Based Consensus Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 844098.	1.3	3
7	Efficacy and tolerability of Brain Stimulation interventions in Borderline Personality Disorder: state of the art and future perspectives – A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 116, 110537.	2.5	14
8	Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review. <i>European Neuropsychopharmacology</i> , 2022, 59, 68-81.	0.3	5
9	Schizophrenia during the COVID-19 pandemic. <i>Current Opinion in Psychiatry</i> , 2021, 34, 203-210.	3.1	41
10	Investigating the Relationship between Autistic Traits, Ruminative Thinking, and Suicidality in a Clinical Sample of Subjects with Bipolar Disorder and Borderline Personality Disorder. <i>Brain Sciences</i> , 2021, 11, 621.	1.1	29
11	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. <i>JAMA Psychiatry</i> , 2021, 78, 550.	6.0	89
12	Delirium in COVID-19 patients: a multicentric observational study in Italy. <i>Neurological Sciences</i> , 2021, 42, 3981-3988.	0.9	10
13	Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 848.	6.0	208
14	Autistic symptoms in people with schizophrenia: Neurocognitive, socio-cognitive, clinical and real-world functional characteristics of individuals without autistic features. <i>Schizophrenia Research</i> , 2021, 236, 12-18.	1.1	4
15	Clinical validation of a combinatorial Pharmacogenomic approach in major Depressive disorder: an Observational prospective Randomized, participant and rater-blinded, controlled trial (PANDORA) $T_j ETQq1 1 0.784314 rgBT \uparrow Overload$		
16	The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. <i>World Psychiatry</i> , 2020, 19, 81-91.	4.8	96
17	T74. RECOVIWEL: AN OBSERVATIONAL STUDY, COMPARING COGNITIVE AND FUNCTIONAL OUTCOMES IN OFFENDERS AND NON-OFFENDERS PATIENTS WITH SEVERE MENTAL ILLNESS. <i>Schizophrenia Bulletin</i> , 2020, 46, S259-S260.	2.3	0
18	Social Cognition in a Research Domain Criteria Perspective: A Bridge Between Schizophrenia and Autism Spectra Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 806.	1.3	27

#	ARTICLE	IF	CITATIONS
19	The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study. <i>European Psychiatry</i> , 2020, 63, e98.	0.1	20
20	The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. <i>Annals of General Psychiatry</i> , 2020, 19, 43.	1.2	54
21	Psychopathological Burden and Quality of Life in Substance Users During the COVID-19 Lockdown Period in Italy. <i>Frontiers in Psychiatry</i> , 2020, 11, 572245.	1.3	50
22	Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release. <i>Psychopharmacology</i> , 2020, 237, 3497-3501.	1.5	10
23	Evidence-Based Integrated Intervention in Patients with Schizophrenia: A Pilot Study of Feasibility and Effectiveness in a Real-World Rehabilitation Setting. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3352.	1.2	19
24	Association study between <i>HTR2A</i> rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. <i>Drug Development Research</i> , 2020, 81, 754-761.	1.4	15
25	Aggressive behavior and metacognitive functions: a longitudinal study on patients with mental disorders. <i>Annals of General Psychiatry</i> , 2020, 19, 36.	1.2	9
26	Change in core symptoms of borderline personality disorder by tDCS: A pilot study. <i>Psychiatry Research</i> , 2020, 291, 113261.	1.7	14
27	Non-pharmacological Approaches to Violence Among People with Severe Mental Disorders. <i>Comprehensive Approach To Psychiatry</i> , 2020, , 269-295.	0.7	0
28	Clinical efficacy of trauma-focused psychotherapies in treatment-resistant depression (TRD) in-patients: A randomized, controlled pilot-study. <i>Psychiatry Research</i> , 2019, 273, 567-574.	1.7	23
29	&#xA0;&#xA0;&#xA0;Rumination, posttraumatic stress disorder, and mood symptoms in borderline personality disorder&#xA0;&#xA0;&#xA0;. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1231-1238.	1.0	34
30	Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates. <i>Frontiers in Pharmacology</i> , 2019, 10, 402.	1.6	35
31	Violence risk and mental disorders (VIORMED-2): A prospective multicenter study in Italy. <i>PLoS ONE</i> , 2019, 14, e0214924.	1.1	22
32	Effectiveness of Cognitive Remediation in Early Versus Chronic Schizophrenia: A Preliminary Report. <i>Frontiers in Psychiatry</i> , 2019, 10, 236.	1.3	13
33	Neuroimaging and Antipsychotics. , 2019, , 267-301.		0
34	The Implementation of Evidence-Based Psychiatric Rehabilitation: Challenges and Opportunities for Mental Health Services. <i>Frontiers in Psychiatry</i> , 2019, 10, 147.	1.3	35
35	Paliperidone extended-release in the short- and long-term treatment of schizophrenia. <i>Rivista Di Psichiatria</i> , 2019, 54, 43-58.	0.6	2
36	Paliperidone palmitate in short- and long-term treatment of schizophrenia. <i>Rivista Di Psichiatria</i> , 2019, 54, 235-248.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Assessing Learning Needs and Career Attitudes of Italian Psychiatry Residents: Results from a National Survey Conducted by the Italian Society of Psychopathology Young Psychiatrists Section (SOPSI-GG). <i>Clinical Practice and Epidemiology in Mental Health</i> , 2019, 15, 21-29.	0.6	3
38	Recovery from schizophrenia. <i>Current Opinion in Psychiatry</i> , 2018, 31, 246-255.	3.1	119
39	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. <i>JAMA Psychiatry</i> , 2018, 75, 396.	6.0	214
40	Correlates of autistic traits among patients with borderline personality disorder. <i>Comprehensive Psychiatry</i> , 2018, 83, 7-11.	1.5	60
41	Feasibility and effectiveness of cognitive remediation in the treatment of borderline personality disorder. <i>Neuropsychological Rehabilitation</i> , 2018, 28, 416-428.	1.0	13
42	The complex relationship between self-reported "personal recovery" and clinical recovery in schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 108-112.	1.1	45
43	Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. <i>Psychological Medicine</i> , 2018, 48, 1359-1366.	2.7	37
44	Looking through autistic features in schizophrenia using the PANSS Autism Severity Score (PAUSS). <i>Psychiatry Research</i> , 2018, 270, 764-768.	1.7	29
45	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. <i>Schizophrenia Research</i> , 2018, 201, 105-112.	1.1	52
46	Factors Associated With Response and Resistance to Cognitive Remediation in Schizophrenia: A Critical Review. <i>Frontiers in Pharmacology</i> , 2018, 9, 1542.	1.6	19
47	Effects of cognitive remediation therapy on neurocognition and negative symptoms in schizophrenia: an Italian naturalistic study. <i>Cognitive Neuropsychiatry</i> , 2017, 22, 53-68.	0.7	6
48	Adult Autism Subthreshold Spectrum (AdAS Spectrum): Validation of a questionnaire investigating subthreshold autism spectrum. <i>Comprehensive Psychiatry</i> , 2017, 73, 61-83.	1.5	79
49	Autism Spectrum Disorder and Schizophrenia: Do They Overlap?. <i>International Journal of Emergency Mental Health</i> , 2016, 18, .	0.3	17
50	Social cognition in people with schizophrenia: a cluster-analytic approach. <i>Psychological Medicine</i> , 2016, 46, 2717-2729.	2.7	65
51	Schizophrenia. <i>Lancet, The</i> , 2016, 388, 1280.	6.3	16
52	Does cognitive remediation modify the use of psychiatric services and the patterns of care of patients with schizophrenia?. <i>Schizophrenia Research</i> , 2016, 175, 85-89.	1.1	5
53	Persistence of effectiveness of cognitive remediation interventions in schizophrenia: A 1-year follow-up study. <i>Schizophrenia Research</i> , 2015, 161, 403-406.	1.1	21
54	The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies. <i>Biological Psychiatry</i> , 2015, 78, 403-412.	0.7	230

#	ARTICLE	IF	CITATIONS
55	Brain Structural Effects of Antidepressant Treatment in Major Depression. <i>Current Neuropharmacology</i> , 2015, 13, 458-465.	1.4	108
56	Cognitive remediation in schizophrenia: background, techniques, evidence of efficacy and perspectives. <i>Epidemiology and Psychiatric Sciences</i> , 2014, 23, 21-25.	1.8	18
57	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014, 13, 275-287.	4.8	346
58	Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 51-57.	1.1	74
59	Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. <i>Schizophrenia Research</i> , 2013, 146, 217-223.	1.1	14
60	Cognitive Remediation in Schizophrenia: Current Status and Future Perspectives. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-12.	0.7	82
61	Cognitive Functioning in Prodromal Psychosis. <i>Archives of General Psychiatry</i> , 2012, 69, 562-71.	13.8	567
62	Cognitive Remediation in the Early Course of Schizophrenia: A Critical Review. <i>Current Pharmaceutical Design</i> , 2012, 18, 534-541.	0.9	28
63	Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: A naturalistic 18-month follow-up study. <i>Psychiatry Research</i> , 2012, 200, 96-101.	1.7	6
64	Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: A prospective study in a real-world setting. <i>Schizophrenia Research</i> , 2011, 133, 223-231.	1.1	57
65	Psychopathologic, neuropsychological and functional outcome measures during cognitive rehabilitation in schizophrenia: A prospective controlled study in a real-world setting. <i>European Psychiatry</i> , 2011, 26, 276-283.	0.1	24
66	Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 745-753.	1.1	31
67	Mitochondrial DNA haplogroups and age at onset of schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 496-501.	1.1	18
68	Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: A pilot case-control association study in an Italian sample. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 287-293.	1.1	35
69	Cognitive Remediation for Schizophrenia: Effectiveness, Core Elements and Moderators of Response. A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0